HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 76.8%

Neg 0% Neu 76.8% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $60.